Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This trial is comparing medical approaches for stroke prevention in people who have atrial
fibrillation (AF) and have undergone a successful procedure called ablation to eliminate or
substantially reduce the arrhythmia. AF is normally associated with an increased risk of
stroke which in many patients can be prevented with appropriate blood thinner therapy. This
trial will compare a strategy of oral anticoagulant therapy after successful ablation to
therapy with an aspirin per day.
Phase:
Phase 4
Details
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Collaborators:
Bayer Biotronik Canada Inc Biotronik SE & Co. KG Canadian Institutes of Health Research (CIHR)